Edmond DE Rothschild Holding S.A. Has $3.39 Million Stock Position in Geron Corporation $GERN

Key Points

• Edmond DE Rothschild Holding S.A. increased its stake in Geron Corporation by 15.1% during the first quarter, owning approximately $3.39 million worth of shares after purchasing an additional 280,000 shares.
• Several hedge funds, including RA Capital Management L.P. and Vanguard Group Inc., have significantly increased their holdings in Geron Corporation, indicating a strong interest from institutional investors.
• Geron reported a revenue increase of 5455.6% year-over-year, posting $49.04 million for the quarter, exceeding expectations while achieving a narrower loss per share compared to the previous year.

Edmond DE Rothschild Holding S.A. grew its stake in Geron Corporation (NASDAQ:GERN - Free Report) by 15.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,130,000 shares of the biopharmaceutical company's stock after purchasing an additional 280,000 shares during the quarter. Edmond DE Rothschild Holding S.A. owned about 0.33% of Geron worth $3,387,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. RA Capital Management L.P. lifted its holdings in Geron by 101.2% during the first quarter. RA Capital Management L.P. now owns 60,379,366 shares of the biopharmaceutical company's stock worth $96,003,000 after acquiring an additional 30,369,830 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Geron by 1.8% during the first quarter. Vanguard Group Inc. now owns 34,146,851 shares of the biopharmaceutical company's stock worth $54,293,000 after acquiring an additional 608,029 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Geron by 20.0% during the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company's stock worth $95,769,000 after acquiring an additional 4,516,615 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Geron by 100.0% during the first quarter. Vestal Point Capital LP now owns 22,005,340 shares of the biopharmaceutical company's stock worth $34,988,000 after acquiring an additional 11,005,340 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in Geron by 6.7% during the fourth quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company's stock worth $47,826,000 after acquiring an additional 847,710 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company's stock.

Geron Stock Performance

GERN opened at $1.38 on Friday. The business's 50-day moving average price is $1.34 and its two-hundred day moving average price is $1.48. Geron Corporation has a 1 year low of $1.09 and a 1 year high of $4.83. The company has a market capitalization of $880.47 million, a price-to-earnings ratio of -10.62 and a beta of 0.63. The company has a debt-to-equity ratio of 0.46, a current ratio of 7.87 and a quick ratio of 6.79.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. Geron had a negative return on equity of 31.37% and a negative net margin of 53.52%.The firm had revenue of $49.04 million for the quarter, compared to the consensus estimate of $47.30 million. During the same quarter last year, the business posted ($0.10) EPS. The company's revenue for the quarter was up 5455.6% on a year-over-year basis. Equities analysts expect that Geron Corporation will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on GERN. The Goldman Sachs Group began coverage on Geron in a report on Thursday, July 10th. They set a "sell" rating and a $1.00 target price on the stock. Scotiabank lowered Geron from a "sector outperform" rating to a "sector perform" rating and reduced their target price for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $4.19.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.